Alimera Sciences Inc., an Atlanta-based ophthalmic pharmaceutical company, raised around $72 million in its IPO. The company sold 6.5 million common shares at $11 per share, compared to original plans to sell 6 million shares bat between $15 and $17 per share.
Alimera will trade on the Nasdaq under ticker symbol ALIM, while Credit Suisse and Citi served as co-lead underwriters.
Alimera has raised just over $71 million in VC funding since 2004, from firms like Scale Venture Partners (18.44% pre-IPO stake), Domain Associates (18.44%), Intersouth Partners (18.44%), Polaris Venture Partners (18.44%) and Venrock Associates (14.93%).
It also received a total of $16.7 million from the sale of two OTC allergy products and a lubricating eye from to Bausch & Lomb. www.alimerasciences.com